Diagnostic Criteria for Secondary Hyperparathyroidism in Chronic Kidney Disease
Secondary hyperparathyroidism is diagnosed when intact parathyroid hormone (PTH) is elevated above stage-specific target ranges in the presence of normal or low serum calcium, after excluding primary hyperparathyroidism and confirming adequate vitamin D status. 1
Core Diagnostic Triad
The diagnosis rests on three simultaneous laboratory findings:
- Elevated intact PTH above the target range for the patient's CKD stage (see table below) 1
- Normal or low serum calcium (typically 8.4–9.5 mg/dL or below), distinguishing it from primary hyperparathyroidism where calcium is elevated 1, 2, 3
- Evidence of the underlying stimulus – most commonly phosphate retention, vitamin D deficiency, or inadequate calcium intake 1, 4, 5
Stage-Specific PTH Target Ranges
The K/DOQI guidelines establish PTH targets that vary by CKD stage 1:
| CKD Stage | eGFR (mL/min/1.73 m²) | Target Intact PTH (pg/mL) |
|---|---|---|
| Stage 3 | 30–59 | 35–70 |
| Stage 4 | 15–29 | 70–110 |
| Stage 5 (dialysis) | <15 or on dialysis | 150–300 |
PTH values persistently above these ranges indicate secondary hyperparathyroidism requiring intervention 1.
Essential Baseline Laboratory Panel
Before confirming secondary hyperparathyroidism, measure 1:
- Serum calcium (corrected for albumin or ionized calcium) – should be normal or low
- Serum phosphorus – often elevated (>4.6 mg/dL in CKD stages 3–4) 1
- Intact PTH – elevated above stage-specific target
- 25-hydroxyvitamin D – must be ≥30 ng/mL to exclude vitamin D deficiency as the primary driver 6, 7
- Serum creatinine and eGFR – to stage CKD and determine PTH target range 1
Excluding Primary Hyperparathyroidism
This step is critical because the biochemical patterns can overlap 6, 2, 3:
- Primary hyperparathyroidism: Elevated or inappropriately normal PTH with hypercalcemia (corrected calcium >10.2 mg/dL) 6, 3
- Secondary hyperparathyroidism: Elevated PTH with normal or low calcium 2, 3
- In primary disease, calcium is typically ≥11.4 mg/dL on average, whereas secondary hyperparathyroidism presents with calcium in the 8.5–9.5 mg/dL range 7
Confirming the Underlying Cause
Secondary hyperparathyroidism does not occur in isolation—identify the stimulus 1, 4, 5:
Chronic Kidney Disease (Most Common)
- PTH rises when eGFR falls below 60 mL/min/1.73 m² due to phosphate retention, impaired calcitriol synthesis, and skeletal resistance to PTH 1, 6, 4
- Serum phosphorus >4.6 mg/dL in stages 3–4 or >5.5 mg/dL in stage 5 confirms phosphate retention 1
Vitamin D Deficiency
- 25-hydroxyvitamin D <30 ng/mL drives secondary hyperparathyroidism by reducing intestinal calcium absorption and impairing PTH suppression 6, 7, 4
- Vitamin D must be repleted before diagnosing CKD-related secondary hyperparathyroidism, as deficiency is a reversible cause 6, 7
Inadequate Calcium Intake
- Dietary calcium <1,000 mg/day can trigger secondary hyperparathyroidism even with normal kidney function and vitamin D 6, 8
- A calcium challenge (600 mg twice daily for 2–3 weeks) that normalizes PTH confirms this diagnosis 8
Monitoring Frequency
Once secondary hyperparathyroidism is diagnosed, the K/DOQI guidelines recommend 1:
- CKD Stage 3: Measure calcium, phosphorus, and PTH every 12 months
- CKD Stage 4: Measure every 3 months
- CKD Stage 5 (dialysis): Measure every 3 months
- More frequent monitoring (monthly) is required when adjusting therapy with vitamin D analogs or phosphate binders 1
PTH Assay Considerations
Intact PTH assays have important limitations 1, 6:
- Overestimation of bioactive PTH: Most "intact" assays detect both PTH(1-84) and inactive C-terminal fragments (7-84), leading to spuriously high values 1
- Assay variability: PTH results can differ by up to 47% between assay generations; always use assay-specific reference ranges 6
- Sample handling: PTH is most stable in EDTA plasma kept at 4°C; serum samples degrade more rapidly 6
- Biological variation: PTH fluctuates by ~20% in healthy individuals and ~30% in dialysis patients; a change >54% (healthy) or >72% (dialysis) is required to be clinically meaningful 6
Common Diagnostic Pitfalls
Pitfall 1: Diagnosing Secondary Hyperparathyroidism Without Checking Vitamin D
- Vitamin D deficiency is the most common reversible cause of elevated PTH 6, 7
- Always confirm 25-hydroxyvitamin D ≥30 ng/mL before attributing PTH elevation to CKD 6, 7
Pitfall 2: Misinterpreting "Normal" PTH in CKD
- The normal range for intact PTH in healthy adults (10–65 pg/mL) does not apply to CKD patients 1
- Attempting to maintain PTH in the "normal" range in CKD stages 3–5 causes adynamic bone disease and increases fracture risk 1
Pitfall 3: Ignoring Calcium Intake
- Even with normal kidney function and vitamin D, inadequate dietary calcium (<1,000 mg/day) can cause secondary hyperparathyroidism 8
- A 2–3 week trial of calcium supplementation (600 mg twice daily) that normalizes PTH confirms this diagnosis 8
Pitfall 4: Overlooking Phosphate Retention
- Hyperphosphatemia directly stimulates PTH secretion and parathyroid hyperplasia independent of calcium and vitamin D 1, 5
- Serum phosphorus >4.6 mg/dL in CKD stages 3–4 requires phosphate binders before PTH can be controlled 1
When Bone Biopsy Is Indicated
Bone biopsy remains the gold standard for diagnosing the specific type of renal osteodystrophy but is reserved for 1:
- Clinical research protocols studying bone disease in CKD
- Discordance between PTH levels and clinical presentation (e.g., fractures despite "appropriate" PTH)
- Suspected adynamic bone disease (PTH <100 pg/mL in dialysis patients with fractures) 1
Routine clinical management does not require biopsy; PTH levels are adequate for screening and guiding therapy 1.